TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of “Moderate Buy” from Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has been given a consensus rating of “Moderate Buy” by the five brokerages that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $50.25.

Several equities research analysts have commented on TGTX shares. JPMorgan Chase & Co. upped their price objective on shares of TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. HC Wainwright initiated coverage on shares of TG Therapeutics in a research note on Monday, October 6th. They issued a “buy” rating and a $60.00 price objective for the company. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday. Wall Street Zen raised TG Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, December 14th. Finally, B. Riley raised TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th.

Insider Activity

In related news, Director Yann Echelard sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $32.57, for a total transaction of $162,850.00. Following the completion of the transaction, the director owned 223,816 shares of the company’s stock, valued at approximately $7,289,687.12. The trade was a 2.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.64% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Man Group plc grew its position in shares of TG Therapeutics by 621.5% during the 3rd quarter. Man Group plc now owns 1,008,462 shares of the biopharmaceutical company’s stock valued at $36,431,000 after purchasing an additional 868,697 shares in the last quarter. Driehaus Capital Management LLC purchased a new position in TG Therapeutics during the first quarter worth about $30,545,000. Woodline Partners LP purchased a new position in TG Therapeutics during the first quarter worth about $21,021,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in TG Therapeutics by 1,221.4% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 422,078 shares of the biopharmaceutical company’s stock worth $15,191,000 after acquiring an additional 390,137 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of TG Therapeutics by 21.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after acquiring an additional 345,059 shares in the last quarter. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $31.07 on Friday. The company has a current ratio of 3.82, a quick ratio of 2.89 and a debt-to-equity ratio of 0.40. The stock has a fifty day simple moving average of $32.16 and a two-hundred day simple moving average of $33.32. TG Therapeutics has a 1-year low of $25.28 and a 1-year high of $46.48. The firm has a market cap of $4.93 billion, a price-to-earnings ratio of 11.18 and a beta of 2.01.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. The firm had revenue of $161.71 million for the quarter, compared to analysts’ expectations of $152.12 million. TG Therapeutics had a return on equity of 133.24% and a net margin of 84.13%.The business’s revenue for the quarter was up 92.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.02 EPS. Analysts anticipate that TG Therapeutics will post 0.08 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.